10:41 uur 22-08-2019

c-LEcta: Succesvolle productbusiness in de eerste helft van 2019

  • Verdere uitbreiding van de productactiviteiten en diversificatie van de portefeuille
  • Aantal verleende octrooien stijgt tot 80
  • Verkoop en verzending naar 25 landen op vier continenten
  • Bovengemiddelde verdere omzetgroei verwacht voor de tweede helft van 2019

LEIPZIG, Duitsland-(BUSINESS WIRE)- c-LEcta, een wereldwijd actief biotechnologiebedrijf met technologisch leiderschap op het gebied van enzymengineering en bioprocesontwikkeling, heeft in de eerste helft van 2019 haar productactiviteiten met succes uitgebreid. Naast omzetstijgingen over de hele portefeuille, kreeg het bedrijf veel nieuwe octrooien toegekend. Terwijl de octrooiportefeuille op het einde van de eerste helft van 2018 nog 59 octrooien telde, bezit het bedrijf uit Leipzig nu meer dan 80 octrooien.

c-LEcta’s DENARASE®, dat wordt gebruikt voor de noodzakelijke verwijdering van nucleïnezuren uit biofarmaceutische producten, presteerde bijzonder goed. DENARASE® is de meest efficiënte technologie op de markt die voldoet aan de strenge wettelijke vereisten voor biofarmaceutische producten. De verkoop van dit product steeg met 164% op jaarbasis in de eerste helft van 2019.

c-LEcta: Successful Product Business in the First Half of 2019

  • Product business further expanded and portfolio diversified
  • Number of granted patents increases to 80
  • Sales and shipping to 25 countries on four continents
  • Above-average further sales growth expected for second half of 2019

LEIPZIG, Germany–(BUSINESS WIRE)– c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully expanded its product business in the first half of 2019. Besides sales increases across the entire portfolio, the company was granted many new patents. While the patent portfolio still comprised 59 granted patents at the end of the first half of 2018, the Leipzig-based company now holds more than 80 patents.

c-LEcta’s DENARASE®, which is used for the necessary removal of nucleic acids from biopharmaceutical products, performed particularly well. DENARASE® is the most efficient technology on the market for meeting the stringent regulatory requirements for biopharmaceutical products. Sales of this product increased by 164% year-on-year in the first half of 2019. The other products in c-LEcta’s portfolio also performed very well and contributed to the positive development of the product business. c-LEcta now markets its self-developed products in 25 countries on four continents. In the first half of 2019, the company recorded more than 150 successful shipments.

For the second half of 2019, c-LEcta expects disproportionately strong sales growth, especially in the food segment. “Our goal in the past fiscal year was to further diversify our products and to develop from a project to a product company. In 2018, we therefore switched our structures to our own sales organization and a versatile product portfolio. This strategic change is now paying off. Our self-developed products are very well received in the market,” explains Dr. Marc Struhalla, CEO and founder of c-LEcta. CFO Thomas Pfaadt adds: “Our products for the food sector in particular will contribute to our growth in the second half of 2019. But we also expect the other products in our portfolio to continue their positive development. We have thus created the basis for raising our sales to a new level in the future.”

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 70 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.


cometis AG

Maximilian Franz

Phone: +49 (0) 611 – 205855 – 22

Fax: +49 (0) 611 – 205855 – 66

e-mail: franz@cometis.de

Check out our twitter: @NewsNovumpr